Eisai scores an FDA approval for a homegrown sleep drug
Eisai’s bet on a better insomnia drug, whose symptoms affect up to a third of all adults, has been rewarded by the FDA with an approval. But with safety being a big issue for sleep drugs, the new therapy faces an uphill climb to gain acceptance with doctors and patients.
Just earlier this year, the FDA imposed black box warnings on a clutch of insomnia drugs, such as Lunesta, Sonata, and Ambien, due to reports of dangerous activity such as sleepwalking and sleep-driving that have led to injuries and deaths.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
